{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-037600","form_type":"8-K","ticker":"HURA","cik":"0001498382","company_name":"TuHURA Biosciences, Inc./NV","filed_at":"2025-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.794108+00:00","generated_at":"2026-05-24T22:18:04.087405+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"TuHURA appoints Dr. Craig Tendler (ex-J&J oncology VP) to Board, effective March 10, 2025","bullets":["Dr. Tendler oversaw 30 major oncology drug approvals at J&J, including DARZALEX, ZYTIGA, and BALVERSA.","Received option to purchase 151,883 shares of HURA common stock at closing price on grant date.","TuHURA plans to begin Phase 3 trial of IFx-2.0 in Q2 2025; Tendler's experience expected to aid regulatory strategy.","Board expanded from five to six members with this appointment."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-037600","json":"https://secwatch.observer/filing/0000950170-25-037600.json","markdown":"https://secwatch.observer/filing/0000950170-25-037600.md","text":"https://secwatch.observer/filing/0000950170-25-037600.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1498382/000095017025037600/0000950170-25-037600-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1498382/000095017025037600/hura-20250307.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T22:18:04.087405+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"65f2295601","claim":"Craig Tendler was appointed as Director at TuHURA Biosciences, Inc./NV.","evidence_excerpt":"On March 7, 2025, the Board of Directors (the “Board”) of TuHURA Biosciences, Inc. (the “Company”) increased the size of the Board from five members to six members and appointed Dr. Craig Tendler to the Board, effective as of March 10, 2025, to serve as a director until the Company’s 2025 Annual Meeting of Stockholders and until his successor has been duly elected and qualified or until his earlier death, resignation or removal.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1498382/000095017025037600/0000950170-25-037600-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}